The company's Phase 1 clinical trial of NKTR-105 in advanced solid tumors will also be featured at ASCO as part of a new poster session, Trials in Progress, at this year's ASCO Annual Meeting.  On Monday, June 7, 2010, a poster titled "Dose-escalation Phase 1 study of NKTR-105, a novel pegylated form of docetaxel" (Abstract #TPS160) will be presented beginning at 8:00 a.m. CT.  NKTR-105 leverages a similar polymer technology to greatly enhance the pharmacologic profile of docetaxel.  Both NKTR-102 and NKTR-105 demonstrate marked reduction in maximum blood concentration with significantly prolonged half-life leading to sustained exposure of the cancer to the active drug.

Nektar To Host Investor Breakfast at ASCO on Monday, June 7, 2010

Nektar will also webcast a presentation to investors and analysts to be held at the 2010 ASCO Meeting on Monday, June 7, 2010 at 8 AM Central Time.  

Panelists at the investor event will include:

Ignace Vergote, M.D., Ph.D., Head of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven, Belgium;Robert Coleman, M.D., Director of Clinical Research, Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; andDaniel Von Hoff, M.D., F.A.C.P., Chief Scientific Officer, TGen Clinical Research Services at Scottsdale Healthcare and U.S. Oncology, and Clinical Professor of Medicine at the University of Arizona College of Medicine and 2010 recipient of the ASCO David A. Karnofsky Memorial Award Lecture.

The event will be accessible live and by replay and can be accessed from the homepage of the company's website at www.nektar beginning on June 7, 2010 at 8:00 AM Central Time.  

SOURCE Nektar Therapeutics